Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback